Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4353460)

Published in BMC Cancer on February 19, 2015

Authors

Jasna Bancovik1, Dayson F Moreira2, Daniel Carrasco3, Jun Yao4, Dale Porter5, Ricardo Moura6, Anamaria Camargo6, Cibely C Fontes-Oliveira7, Miguel G Malpartida8, Silvia Carambula9, Edouard Vannier10, Bryan E Strauss11, Alda Wakamatsu12, Venancio Af Alves13, Angela F Logullo14, Fernando A Soares15, Kornelia Polyak16, José E Belizário17

Author Affiliations

1: Department of Pharmacology, Institute of Biomedical Sciences - University of São Paulo, Av Lineu Prestes 1524, 05508-900, São Paulo, SP, Brazil. jasnam@ibiss.bg.ac.rs.
2: Department of Pharmacology, Institute of Biomedical Sciences - University of São Paulo, Av Lineu Prestes 1524, 05508-900, São Paulo, SP, Brazil. dmoreira@coh.org.
3: Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute - Harvard Medical School, 450 Brookline Ave. D740C, Boston, MA, 02215, USA. daniel_eduardo_carrasco@hotmail.com.
4: Department of Neuro-Oncology Research, Division of Cancer Medicine, University of Texas - MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. JYao1@mdanderson.org.
5: Oncology Disease Area and Developmental and Molecular Pathways Group, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA. dale.porter@novartis.com.
6: Ludwig Institute for Cancer Research- Hospital Sírio-Libanês, Rua Peixoto Gomide, 316, 7th floor, 01409-000, São Paulo, SP, Brazil. anamaria@compbio.ludwig.org.br.
7: Department of Pharmacology, Institute of Biomedical Sciences - University of São Paulo, Av Lineu Prestes 1524, 05508-900, São Paulo, SP, Brazil. ccristine@gmail.com.
8: Department of Pharmacology, Institute of Biomedical Sciences - University of São Paulo, Av Lineu Prestes 1524, 05508-900, São Paulo, SP, Brazil. hmgaray@usp.br.
9: Division of Geographic Medicine & Infectious Diseases, Tufts Medical Center, 25 Harvard Street - Tupper 729, Boston, MA, 02111, USA. scarambula@gmail.com.
10: Division of Geographic Medicine & Infectious Diseases, Tufts Medical Center, 25 Harvard Street - Tupper 729, Boston, MA, 02111, USA. evannier@tuftsmedicalcenter.org.
11: The Cancer Institute of São Paulo, Av. Dr. Arnaldo, 251, 8th floor, 01246-000, Sao Paulo, SP, Brazil. bstrrauss@usp.br.
12: Department of Pathology - School of Medicine, University of São Paulo, Avenida Dr Enéas de Carvalho Aguiar, 155 - 10th floor, 05403-000, Sao Paulo, SP, Brazil. awakamatsu@uol.com.br.
13: Department of Pathology - School of Medicine, University of São Paulo, Avenida Dr Enéas de Carvalho Aguiar, 155 - 10th floor, 05403-000, Sao Paulo, SP, Brazil. venancio@uol.com.br.
14: Department of Pathology - Paulista School of Medicine, Federal University of São Paulo, Rua Sena Madureira, 1500, 04021-001, São Paulo, SP, Brazil. waitzberg.angela@gmail.com.
15: Department of Pathology - AC Camargo Cancer Center, Rua Professor Antônio Prudente, 211, 01509-010, São Paulo, SP, Brazil. fasoares@me.com.
16: Department of Medical Oncology, Dana-Farber Cancer Institute - Harvard Medical School, 450 Brookline Ave. D740C, Boston, MA, 02215, USA. Kornelia_Polyak@dfci.harvard.edu.
17: Department of Pharmacology, Institute of Biomedical Sciences - University of São Paulo, Av Lineu Prestes 1524, 05508-900, São Paulo, SP, Brazil. jebeliza@usp.br.

Articles cited by this

Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res (2002) 28.38

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36

EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39

Mass-spectrometry-based draft of the human proteome. Nature (2014) 6.32

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res (2007) 5.01

Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46

Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol (2001) 2.29

ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol (2007) 2.18

Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res (2008) 1.82

Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin. J Cell Biol (2006) 1.62

Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol (2007) 1.59

Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res (2000) 1.45

cDNA and genomic cloning of lacritin, a novel secretion enhancing factor from the human lacrimal gland. J Mol Biol (2001) 1.44

A neural survival factor is a candidate oncogene in breast cancer. Proc Natl Acad Sci U S A (2003) 1.41

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res (2003) 1.35

Restricted epithelial proliferation by lacritin via PKCalpha-dependent NFAT and mTOR pathways. J Cell Biol (2006) 1.33

ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia (2008) 1.20

Identification of a survival-promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin. J Neurosci (1998) 1.20

Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. Antimicrob Agents Chemother (2006) 1.18

Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg (2000) 1.10

Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells. Exp Neurol (2002) 1.09

Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. Br J Dermatol (2004) 1.04

Production and characterization of a monoclonal antibody for sweat-specific protein and its application for sweat identification. Int J Legal Med (2002) 1.04

Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia. Prostate (2007) 1.03

Dermcidin expression in hepatic cells improves survival without N-glycosylation, but requires asparagine residues. Br J Cancer (2006) 1.01

Generation of multiple stable dermcidin-derived antimicrobial peptides in sweat of different body sites. J Invest Dermatol (2006) 0.99

Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer (1999) 0.97

Immunohistochemical staining of cutaneous tumours with G-81, a monoclonal antibody to dermcidin. Br J Dermatol (2004) 0.93

Crystal structure and functional mechanism of a human antimicrobial membrane channel. Proc Natl Acad Sci U S A (2013) 0.91

Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res (2004) 0.90

Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology (2011) 0.89

Identification of dermcidin in human gestational tissue and characterization of its proteolytic activity. Biochem Biophys Res Commun (2007) 0.88

Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines. Br J Cancer (2008) 0.87

The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival. Curr Opin Clin Nutr Metab Care (2008) 0.85

Genes up- and down-regulated by dermcidin in breast cancer: a microarray analysis. Genet Mol Res (2008) 0.83

Expression of a novel lacrimal gland gene lacritin in human breast tissues. J Cancer Res Clin Oncol (2003) 0.83

Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation. Mol Endocrinol (2008) 0.81

Prediction and biochemical characterization of intrinsic disorder in the structure of proteolysis-inducing factor/dermcidin. Genet Mol Res (2007) 0.78

Cutaneous mixed tumors: an immunohistochemical study using two antibodies, G-81 and C8/144B. J Dermatol Sci (2004) 0.76